Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Other Operating Expenses: 2012-2025

Historic Other Operating Expenses for Heron Therapeutics (HRTX) over the last 10 years, with Sep 2025 value amounting to $12.9 million.

  • Heron Therapeutics' Other Operating Expenses rose 17.95% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.9 million, marking a year-over-year decrease of 0.97%. This contributed to the annual value of $47.1 million for FY2024, which is 30.39% down from last year.
  • Per Heron Therapeutics' latest filing, its Other Operating Expenses stood at $12.9 million for Q3 2025, which was up 11.81% from $11.6 million recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Other Operating Expenses peaked at $39.1 million during Q2 2022, and registered a low of $11.0 million during Q3 2024.
  • Over the past 3 years, Heron Therapeutics' median Other Operating Expenses value was $12.3 million (recorded in 2023), while the average stood at $13.8 million.
  • Per our database at Business Quant, Heron Therapeutics' Other Operating Expenses skyrocketed by 85.71% in 2021 and then crashed by 49.83% in 2022.
  • Over the past 5 years, Heron Therapeutics' Other Operating Expenses (Quarterly) stood at $35.4 million in 2021, then plummeted by 49.83% to $17.8 million in 2022, then crashed by 30.64% to $12.3 million in 2023, then decreased by 10.31% to $11.1 million in 2024, then rose by 17.95% to $12.9 million in 2025.
  • Its Other Operating Expenses stands at $12.9 million for Q3 2025, versus $11.6 million for Q2 2025 and $12.3 million for Q1 2025.